# Adaptive Biotechnologies Corp: financial statements, quarterly

ADPT · Nasdaq · CIK 1478320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adpt.md) · [Financials](/companies/adpt/financials.md) · [Filings](/companies/adpt/filings.md) · [Insiders](/companies/adpt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adpt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [37.9](/filings/0000950170-24-123423.md) | [45.8 d](/filings/0001193125-26-076902.md) | [41.9](/filings/0000950170-25-061897.md) | [43.2](/filings/0000950170-25-103120.md) | [46.4](/filings/0001193125-25-267061.md) | [47.5 d](/filings/0001193125-26-076902.md) | [52.4](/filings/0001193125-26-206546.md) | [58.9](/filings/0001193125-26-332940.md) | [94.0](/filings/0001193125-25-267061.md) | [71.7 d](/filings/0001193125-26-076902.md) | [70.9](/filings/0001193125-26-206546.md) | [71.6](/filings/0001193125-26-332940.md) |
| Cost of revenue | $m | [19.3](/filings/0000950170-24-123423.md) | [19.6 d](/filings/0001193125-26-076902.md) | [18.1](/filings/0000950170-25-061897.md) | [19.3](/filings/0000950170-25-103120.md) | [16.7](/filings/0001193125-25-267061.md) | [18.0 d](/filings/0001193125-26-076902.md) | [17.0](/filings/0001193125-26-206546.md) | [18.0](/filings/0001193125-26-332940.md) | [18.2](/filings/0001193125-25-267061.md) | [18.2 d](/filings/0001193125-26-076902.md) | [18.7](/filings/0001193125-26-206546.md) | [20.2](/filings/0001193125-26-332940.md) |
| Research and development | $m | [28.5](/filings/0000950170-24-123423.md) | [28.7 d](/filings/0001193125-26-076902.md) | [30.2](/filings/0000950170-25-061897.md) | [25.4](/filings/0000950170-25-103120.md) | [24.2](/filings/0001193125-25-267061.md) | [23.2 d](/filings/0001193125-26-076902.md) | [24.2](/filings/0001193125-26-206546.md) | [24.1](/filings/0001193125-26-332940.md) | [23.7](/filings/0001193125-25-267061.md) | [21.8 d](/filings/0001193125-26-076902.md) | [23.6](/filings/0001193125-26-206546.md) | [19.2](/filings/0001193125-26-332940.md) |
| Operating income | $m | [(51.0)](/filings/0000950170-24-123423.md) | [(71.1) d](/filings/0001193125-26-076902.md) | [(48.8)](/filings/0000950170-25-061897.md) | [(47.3)](/filings/0000950170-25-103120.md) | [(32.6)](/filings/0001193125-25-267061.md) | [(33.8) d](/filings/0001193125-26-076902.md) | [(29.6)](/filings/0001193125-26-206546.md) | [(25.0)](/filings/0001193125-26-332940.md) | [10.3](/filings/0001193125-25-267061.md) | [(12.8) d](/filings/0001193125-26-076902.md) | [(19.2)](/filings/0001193125-26-206546.md) | [(15.8)](/filings/0001193125-26-332940.md) |
| Interest expense | $m | [3.7](/filings/0000950170-24-123423.md) | [3.0 d](/filings/0001193125-26-076902.md) | [3.0](/filings/0000950170-25-061897.md) | [2.7](/filings/0000950170-25-103120.md) | [2.9](/filings/0001193125-25-267061.md) | [3.0 d](/filings/0001193125-26-076902.md) | [2.9](/filings/0001193125-26-206546.md) | [2.9](/filings/0001193125-26-332940.md) | [3.0](/filings/0001193125-25-267061.md) | [3.0 d](/filings/0001193125-26-076902.md) | [2.9](/filings/0001193125-26-206546.md) | [2.7](/filings/0001193125-26-332940.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(50.3)](/filings/0000950170-24-123423.md) | [(69.4) d](/filings/0001193125-26-076902.md) | [(47.5)](/filings/0000950170-25-061897.md) | [(46.2)](/filings/0000950170-25-103120.md) | [(32.1)](/filings/0001193125-25-267061.md) | [(33.7) d](/filings/0001193125-26-076902.md) | [(29.9)](/filings/0001193125-26-206546.md) | [(25.6)](/filings/0001193125-26-332940.md) | [9.5](/filings/0001193125-25-267061.md) | [(13.6) d](/filings/0001193125-26-076902.md) | [(20.0)](/filings/0001193125-26-206546.md) | [(39.8)](/filings/0001193125-26-332940.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0000950170-24-123423.md) | not reported | [(0.33)](/filings/0000950170-25-061897.md) | [(0.31)](/filings/0000950170-25-103120.md) | [(0.22)](/filings/0001193125-25-267061.md) | not reported | [(0.20)](/filings/0001193125-26-206546.md) | [(0.17)](/filings/0001193125-26-332940.md) | [0.06](/filings/0001193125-25-267061.md) | not reported | [(0.13)](/filings/0001193125-26-206546.md) | [(0.25)](/filings/0001193125-26-332940.md) |
| Basic EPS | $ per share | [(0.35)](/filings/0000950170-24-123423.md) | not reported | [(0.33)](/filings/0000950170-25-061897.md) | [(0.31)](/filings/0000950170-25-103120.md) | [(0.22)](/filings/0001193125-25-267061.md) | not reported | [(0.20)](/filings/0001193125-26-206546.md) | [(0.17)](/filings/0001193125-26-332940.md) | [0.06](/filings/0001193125-25-267061.md) | not reported | [(0.13)](/filings/0001193125-26-206546.md) | [(0.25)](/filings/0001193125-26-332940.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [88.7](/filings/0000950170-23-062136.md) | [65.1](/filings/0000950170-25-030913.md) | [71.2](/filings/0000950170-24-054604.md) | [59.8](/filings/0000950170-24-089342.md) | [38.1](/filings/0000950170-24-123423.md) | [47.9](/filings/0001193125-26-076902.md) | [50.6](/filings/0001193125-26-206546.md) | [43.2](/filings/0001193125-26-332940.md) | [55.0](/filings/0001193125-25-267061.md) | [70.5](/filings/0001193125-26-332940.md) | [77.6](/filings/0001193125-26-206546.md) | [170](/filings/0001193125-26-332940.md) |
| Current assets | $m | [435](/filings/0000950170-23-062136.md) | [410](/filings/0000950170-25-030913.md) | [374](/filings/0000950170-24-054604.md) | [352](/filings/0000950170-24-089342.md) | [308](/filings/0000950170-24-123423.md) | [284](/filings/0001193125-26-076902.md) | [256](/filings/0000950170-25-061897.md) | [262](/filings/0000950170-25-103120.md) | [281](/filings/0001193125-25-267061.md) | [300](/filings/0001193125-26-332940.md) | [292](/filings/0001193125-26-206546.md) | [421](/filings/0001193125-26-332940.md) |
| Total assets | $m | [718](/filings/0000950170-23-062136.md) | [661](/filings/0000950170-25-030913.md) | [620](/filings/0000950170-24-054604.md) | [585](/filings/0000950170-24-089342.md) | [559](/filings/0000950170-24-123423.md) | [539](/filings/0001193125-26-076902.md) | [511](/filings/0000950170-25-061897.md) | [497](/filings/0000950170-25-103120.md) | [491](/filings/0001193125-25-267061.md) | [513](/filings/0001193125-26-332940.md) | [506](/filings/0001193125-26-206546.md) | [641](/filings/0001193125-26-332940.md) |
| Current liabilities | $m | [93.3](/filings/0000950170-23-062136.md) | [88.0](/filings/0000950170-25-030913.md) | [83.0](/filings/0000950170-24-054604.md) | [88.1](/filings/0000950170-24-089342.md) | [87.6](/filings/0000950170-24-123423.md) | [98.1](/filings/0001193125-26-076902.md) | [87.8](/filings/0000950170-25-061897.md) | [92.1](/filings/0000950170-25-103120.md) | [83.4](/filings/0001193125-25-267061.md) | [89.9](/filings/0001193125-26-332940.md) | [87.0](/filings/0001193125-26-206546.md) | [87.7](/filings/0001193125-26-332940.md) |
| Total liabilities | $m | [356](/filings/0000950170-23-062136.md) | [353](/filings/0000950170-25-030913.md) | [346](/filings/0000950170-24-054604.md) | [343](/filings/0000950170-24-089342.md) | [335](/filings/0000950170-24-123423.md) | [337](/filings/0001193125-26-076902.md) | [321](/filings/0000950170-25-061897.md) | [317](/filings/0000950170-25-103120.md) | [286](/filings/0001193125-25-267061.md) | [288](/filings/0001193125-26-332940.md) | [282](/filings/0001193125-26-206546.md) | [490](/filings/0001193125-26-332940.md) |
| Long-term debt | $m | [127](/filings/0000950170-23-062136.md) | [131](/filings/0000950170-25-030913.md) | [132](/filings/0000950170-24-054604.md) | [132](/filings/0000950170-24-089342.md) | [133](/filings/0000950170-24-123423.md) | [132](/filings/0001193125-26-076902.md) | [132](/filings/0000950170-25-061897.md) | [130](/filings/0000950170-25-103120.md) | [129](/filings/0001193125-25-267061.md) | [127](/filings/0001193125-26-332940.md) | [125](/filings/0001193125-26-206546.md) | [0.0](/filings/0001193125-26-332940.md) |
| Current portion of debt | $m | [3.2](/filings/0000950170-23-062136.md) | not reported | not reported | not reported | not reported | [0.9](/filings/0001193125-26-076902.md) | [2.0](/filings/0000950170-25-061897.md) | [3.1](/filings/0000950170-25-103120.md) | [2.4](/filings/0001193125-25-267061.md) | [4.6](/filings/0001193125-26-332940.md) | [5.8](/filings/0001193125-26-206546.md) | [0.0](/filings/0001193125-26-332940.md) |
| Shareholders' equity | $m | [362](/filings/0000950170-23-062136.md) | [308](/filings/0000950170-25-030913.md) | [275](/filings/0000950170-24-054604.md) | [242](/filings/0000950170-24-089342.md) | [224](/filings/0000950170-24-123423.md) | [203](/filings/0001193125-26-076902.md) | [190](/filings/0000950170-25-061897.md) | [180](/filings/0000950170-25-103120.md) | [204](/filings/0001193125-25-267061.md) | [219](/filings/0001193125-26-332940.md) | [216](/filings/0001193125-26-206546.md) | [143](/filings/0001193125-26-332940.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(46.7) d](/filings/0000950170-24-123423.md) | [(26.9) d](/filings/0001193125-26-076902.md) | [(38.4)](/filings/0000950170-25-061897.md) | [(17.3) d](/filings/0000950170-25-103120.md) | [(27.1) d](/filings/0001193125-25-267061.md) | [(12.5) d](/filings/0001193125-26-076902.md) | [(28.5)](/filings/0001193125-26-206546.md) | [(12.4) d](/filings/0001193125-26-332940.md) | [(7.1) d](/filings/0001193125-25-267061.md) | [2.1 d](/filings/0001193125-26-076902.md) | [(9.5)](/filings/0001193125-26-206546.md) | [(6.4) d](/filings/0001193125-26-332940.md) |
| Capital expenditure | $m | [2.8 d](/filings/0000950170-24-123423.md) | [1.3 d](/filings/0001193125-26-076902.md) | [1.5](/filings/0000950170-25-061897.md) | [1.7 d](/filings/0000950170-25-103120.md) | [0.3 d](/filings/0001193125-25-267061.md) | [0.1 d](/filings/0001193125-26-076902.md) | [1.3](/filings/0001193125-26-206546.md) | [0.7 d](/filings/0001193125-26-332940.md) | [0.4 d](/filings/0001193125-25-267061.md) | [0.6 d](/filings/0001193125-26-076902.md) | [0.8](/filings/0001193125-26-206546.md) | [1.2 d](/filings/0001193125-26-332940.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [143](/filings/0000950170-23-062136.md) | [144](/filings/0000950170-24-054604.md) | [144](/filings/0000950170-24-089342.md) | [145](/filings/0000950170-24-123423.md) | [146](/filings/0000950170-25-061897.md) | [147](/filings/0000950170-25-103120.md) | [148](/filings/0001193125-25-267061.md) | [149](/filings/0001193125-26-206546.md) | [152](/filings/0001193125-26-332940.md) | [163](/filings/0001193125-25-267061.md) | [156](/filings/0001193125-26-206546.md) | [160](/filings/0001193125-26-332940.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 159,595,842 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332940.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.